.
NAVB financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
247 996 | 315 011 | 210 730 | 239 485 | 125 480 | 69 940 | 58 173 | 22 170 | 17 416 | 61 185 | 23 604 |
EV * |
225 808 | 315 579 | 205 459 | 267 928 | 179 393 | 130 000 | 57 732 | 19 010 | 16 675 | 59 259 | 59 259 |
Stock price $ |
54.8 | 63.6 | 34.6 | 32.2 | 16.6 | 9 | 7.2 | 2.6 | 1.21 | 2.18 | 0.841 |
Number of shares * |
4 525 | 4 953 | 6 090 | 7 437 | 7 559 | 7 771 | 8 080 | 8 527 | 14 393 | 28 066 | 28 066 |
EPS |
1,24 | -5,89 | -7,01 | -4,80 | -3,65 | -1,84 | 9,28 | -1,89 | -0,76 | -0,38 | -0,38 |
Revenue * |
598 | 79 | 1 131 | 6 275 | 13 249 | 21 970 | 1 810 | 1 169 | 658 | 915 | 915 |
Net income * |
5 613 | -29 157 | -42 700 | -35 727 | -27 563 | -14 308 | 74 946 | -16 114 | -10 948 | -10 722 | -10 722 |
Operating profit * |
-24 104 | -27 989 | -38 438 | -27 633 | -18 551 | -2 223 | -13 877 | -10 847 | -10 963 | -10 711 | -10 711 |
Total liabilities * |
10 062 | 13 378 | 44 326 | 41 724 | 68 800 | 80 128 | 8 733 | 4 611 | 5 032 | 5 711 | 5 711 |
Net debt * |
-22 182 | 568 | -5 271 | 28 444 | 53 913 | 60 060 | -441 | -2 571 | 22 | -1 334 | -1 334 |
Total assets * |
31 194 | 11 972 | 40 317 | 11 920 | 14 965 | 12 462 | 20 781 | 7 022 | 4 151 | 7 758 | 7 758 |
Equity * |
21 132 | -1 405 | -4 010 | -29 803 | -54 305 | -68 135 | 11 380 | 1 742 | -1 612 | 1 316 | 1 316 |
Cash and investments * |
28 644 | 9 119 | 32 939 | 5 479 | 7 166 | 1 539 | 4 593 | 4 275 | 1 047 | 2 670 | 2 670 |
Over the past 10 years, the maximum capitalization of Navidea Biopharmaceuticals, Inc. is 315 011, the minimum is 17 416. Maximum net income 74 946, Minimum net income -42 700. The maximum price of NAVB shares is 63.6, the minimum price is 1.21.
.
NAVB valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
44,18 | -10,80 | -4,94 | -6,70 | -4,55 | -4,89 | 0,78 | -1,38 | -1,59 | -5,71 | -2,20 |
P/B |
11,74 | -224,15 | -52,56 | -8,04 | -2,31 | -1,03 | 5,11 | 12,73 | -10,80 | 46,51 | 17,94 |
P/S |
414,90 | 4 000,75 | 186,38 | 38,17 | 9,47 | 3,18 | 32,13 | 18,96 | 26,48 | 66,87 | 25,80 |
E/P |
2% | -9% | -20% | -15% | -22% | -20% | 129% | -73% | -63% | -18% | -45% |
P/FCF |
-15,26 | -12,81 | -5,71 | -7,90 | -6,56 | 19,67 | 0,99 | 5,24 | -1,85 | -7,12 | -2,75 |
.
NAVB profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
27% | 2 075% | 1 065% | 120% | 51% | 21% | 659% | -925% | 679% | -815% | |
ROA |
18% | -245% | -106% | -304% | -187% | -117% | 369% | -244% | -291% | -150% | |
ROIC |
-87% | -484% | -132% | -978% | -211% | 4% | -109% | -298% | -3 308% | -352% |